Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balch, C. M.
Right arrow Articles by Durant, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balch, C. M.
Right arrow Articles by Durant, J. R.

Journal of Clinical Oncology, Vol 1, 126-134, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)

CM Balch, SJ Soong, TM Murad, JW Smith, WA Maddox and JR Durant

A multifactorial analysis of 200 cutaneous melanoma patients with distant metastasis (stage III) was performed on 13 clinical and pathological factors using the Cox regression analysis. There were only three dominant prognostic variables that independently predicted the patient's clinical course: (1) number of metastatic sites (1 vs. 2 vs. greater than or equal to 3, p less than 0.00001), (2) remission duration (less than 12 mo vs. greater than or equal to 12 mo, p = 0.0186), and (3) the location of the metastases (visceral vs. nonvisceral vs. combined, p = 0.0192). Factors that were not significant in the multifactorial analysis included the patients' age and sex, the site of the primary melanoma, the sequence of metastases, and all histopathological features of the primary melanoma (thickness, level of invasion, ulceration, growth pattern, pigmentation, and lymphocyte infiltration). For a single metastatic site, the 1-yr survival rate was 36%, while it was only 13% for 2 sites, and 0% for greater than or equal to 3 sites (p less than 0.00001). The 1-yr survival for patients was 40% for nonvisceral sites (skin, subcutaneous, distant lymph nodes) compared to only 11% for visceral metastases and 8% for combined sites (p less than 0.00001). Pulmonary metastases were associated with a significantly higher survival rate than metastatic melanoma in any other visceral site. The most common first site of distant metastases (either alone or in combination) was skin (38%), lung (36%), liver (20%), and brain (20%). The skin, subcutaneous and distant lymph node group was the first site of metastases in 59% of patients. This finding emphasizes the importance of careful physical exams in routine metastatic evaluations. Only a minority (25%) of stage I patients progressed to stage III disease after a median interval of 2.8 years. In contrast, the majority (75%) of melanoma patients with nodal metastases (stage II) progressed to stage III disease after a median duration of only 11 mo. Of the patients who eventually developed stage III disease, 95% of those who initially presented with stage II disease progressed within 3 yr, while stage I patients who progressed to stage III did not reach a 95% cumulative incidence until 8 yr.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
H. B. Neuman, A. Patel, N. Ishill, C. Hanlon, M. S. Brady, A. C. Halpern, A. Houghton, and D. G. Coit
A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma
Ann. Surg. Oncol., July 1, 2008; 15(7): 2034 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
L. K. Jacobs, J. R. Lange, and C. M. Balch
Sorting Through the Heterogeneity of Recurrent Melanoma
Ann. Surg. Oncol., May 1, 2008; 15(5): 1280 - 1281.
[Full Text] [PDF]

Home page
 JCOHome page
E. L. Korn, P.-Y. Liu, S. J. Lee, J.-A. W. Chapman, D. Niedzwiecki, V. J. Suman, J. Moon, V. K. Sondak, M. B. Atkins, E. A. Eisenhauer, et al.
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
J. Clin. Oncol., February 1, 2008; 26(4): 527 - 534.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Balch and S.-j. Soong
Predicting Outcomes in Metastatic Melanoma
J. Clin. Oncol., January 10, 2008; 26(2): 168 - 169.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H. B. Neuman, A. Patel, C. Hanlon, J. D. Wolchok, A. N. Houghton, and D. G. Coit
Stage-IV Melanoma and Pulmonary Metastases: Factors Predictive of Survival
Ann. Surg. Oncol., October 1, 2007; 14(10): 2847 - 2853.
[Abstract] [Full Text] [PDF]

Home page
 Emerg. Med. J.Home page
A. K Agarwal, R. Garg, and M. Simon
Ring enhancing lesion on CT scan: metastases or a brain abscess?
Emerg. Med. J., October 1, 2007; 24(10): 706 - 706.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. P. Petersen, S. I. Hanish, J. C. Haney, C. C. Miller III, W. R. Burfeind Jr, D. S. Tyler, H. F. Seigler, W. Wolfe, T. A. D'Amico, and D. H. Harpole Jr
Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma
J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 104 - 110.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
F. Tas, S. Kurul, H. Camlica, and E. Topuz
Malignant Melanoma in Turkey: A Single Institution's Experience on 475 Cases
Jpn. J. Clin. Oncol., December 1, 2006; 36(12): 794 - 799.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Z. Belhocine, A. M. Scott, E. Even-Sapir, J.-L. Urbain, and R. Essner
Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
J. Nucl. Med., June 1, 2006; 47(6): 957 - 967.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. W. Weber, S. O'Day, M. Rose, R. Deck, P. Ames, J. Good, J. Meyer, R. Allen, S. Trautvetter, M. Timmerman, et al.
Low-Dose Outpatient Chemobiotherapy With Temozolomide, Granulocyte-Macrophage Colony Stimulating Factor, Interferon-{alpha}2b, and Recombinant Interleukin-2 for the Treatment of Metastatic Melanoma
J. Clin. Oncol., December 10, 2005; 23(35): 8992 - 9000.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. P. Livestro, A. Muzikansky, E. M. Kaine, T. J. Flotte, A. J. Sober, M. C. Mihm Jr, J. S. Michaelson, A. B. Cosimi, and K. K. Tanabe
Biology of Desmoplastic Melanoma: A Case-Control Comparison With Other Melanomas
J. Clin. Oncol., September 20, 2005; 23(27): 6739 - 6746.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. M. Pawlik, M. I. Ross, M. M. Johnson, C. W. Schacherer, D. M. McClain, P. F. Mansfield, J. E. Lee, J. N. Cormier, and J. E. Gershenwald
Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy
Ann. Surg. Oncol., August 1, 2005; 12(8): 587 - 596.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
R. Essner, J. H. Lee, L. A. Wanek, H. Itakura, and D. L. Morton
Contemporary Surgical Treatment of Advanced-Stage Melanoma
Arch Surg, September 1, 2004; 139(9): 961 - 967.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
B. Taback, S. J. O'Day, P. D. Boasberg, S. Shu, P. Fournier, R. Elashoff, H.-J. Wang, and D. S. B. Hoon
Circulating DNA Microsatellites: Molecular Determinants of Response to Biochemotherapy in Patients With Metastatic Melanoma
J Natl Cancer Inst, January 21, 2004; 96(2): 152 - 156.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Froidevaux, M. Calame-Christe, J. Schuhmacher, H. Tanner, R. Saffrich, M. Henze, and A. N. Eberle
A Gallium-Labeled DOTA-{alpha}-Melanocyte- Stimulating Hormone Analog for PET Imaging of Melanoma Metastases
J. Nucl. Med., January 1, 2004; 45(1): 116 - 123.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Froidevaux, M. Calame-Christe, H. Tanner, L. Sumanovski, and A. N. Eberle
A Novel DOTA-{alpha}-Melanocyte-Stimulating Hormone Analog for Metastatic Melanoma Diagnosis
J. Nucl. Med., December 1, 2002; 43(12): 1699 - 1706.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. J. Allen and D. G. Coit
The Surgical Management of Metastatic Melanoma
Ann. Surg. Oncol., October 1, 2002; 9(8): 762 - 770.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
K. Nakaya, R. Mizuno, and T. Ohhashi
B16-BL6 melanoma cells release inhibitory factor(s) of active pump activity in isolated lymph vessels
Am J Physiol Cell Physiol, December 1, 2001; 281(6): C1812 - C1818.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Balch, S.-J. Soong, J. E. Gershenwald, J. F. Thompson, D. S. Reintgen, N. Cascinelli, M. Urist, K. M. McMasters, M. I. Ross, J. M. Kirkwood, et al.
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
J. Clin. Oncol., August 15, 2001; 19(16): 3622 - 3634.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Manola, M. Atkins, J. Ibrahim, and J. Kirkwood
Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials
J. Clin. Oncol., November 15, 2000; 18(22): 3782 - 3793.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. E. Spitler, M. L. Grossbard, M. S. Ernstoff, G. Silver, M. Jacobs, F. A. Hayes, and S. J. Soong
Adjuvant Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage Colony-Stimulating Factor
J. Clin. Oncol., April 1, 2000; 18(8): 1614 - 1621.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Samur and P. Butow
Prognosis of Metastatic Melanoma: Where Are the Details?
J. Clin. Oncol., December 1, 1999; 17(12): 3856 - 3860.
[Full Text] [PDF]

Home page
 RadiologyHome page
S. P. Blake, K. Weisinger, M. B. Atkins, and V. Raptopoulos
Liver Metastases from Melanoma: Detection with Multiphasic Contrast-enhanced CT
Radiology, October 1, 1999; 213(1): 92 - 96.
[Abstract] [Full Text]

Home page
 JCOHome page
S. J. O'Day, G. Gammon, P. D. Boasberg, M. A. Martin, T. S. Kristedja, M. Guo, S. Stern, S. Edwards, P. Fournier, M. Weisberg, et al.
Advantages of Concurrent Biochemotherapy Modified by Decrescendo Interleukin-2, Granulocyte Colony-Stimulating Factor, and Tamoxifen for Patients With Metastatic Melanoma
J. Clin. Oncol., September 1, 1999; 17(9): 2752 - 2752.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, et al.
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
J. Clin. Oncol., July 1, 1999; 17(7): 2105 - 2105.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
M. H. Terhune, N. Swanson, and T. M. Johnson
Use of Chest Radiography in the Initial Evaluation of Patients With Localized Melanoma
Arch Dermatol, May 1, 1998; 134(5): 569 - 572.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1983 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online